Innovative Pharmaceutical Biotech (HKG:0399) expects to swing to a loss for the year ended March 31, according to a bourse filing Monday.
Shares declined 5% in morning trade Tuesday.
The pharma company is estimating a loss of between HK$550 million and HK$600 million, which compares to a profit of HK$98.7 million for fiscal 2024.
The company attributed the loss to a "significant impairment loss" on an intangible asset.
Innovative Pharmaceutical expects to report its annual results at the end of June.
Meanwhile, the company said its oral insulin product is now expected to enter the market in the third quarter of 2028.
The company had originally planned to commercialize the product in the first quarter of 2026, but said was delayed due to difficulty in onboarding subjects into its phase 3 clinical trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。